JP2009525757A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525757A5 JP2009525757A5 JP2008554373A JP2008554373A JP2009525757A5 JP 2009525757 A5 JP2009525757 A5 JP 2009525757A5 JP 2008554373 A JP2008554373 A JP 2008554373A JP 2008554373 A JP2008554373 A JP 2008554373A JP 2009525757 A5 JP2009525757 A5 JP 2009525757A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- amino acid
- protein
- phosphatase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 150000001413 amino acids Chemical group 0.000 claims 8
- 102000004097 Protein phosphatase inhibitor 1 Human genes 0.000 claims 7
- 108090000506 Protein phosphatase inhibitor 1 Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 210000004165 myocardium Anatomy 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000010247 heart contraction Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000006371 metabolic abnormality Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77232706P | 2006-02-10 | 2006-02-10 | |
| PCT/US2007/003470 WO2007100465A2 (en) | 2006-02-10 | 2007-02-09 | Phosphatase inhibitor protein-1 as a regulator of cardiac function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012207821A Division JP2013027398A (ja) | 2006-02-10 | 2012-09-21 | 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009525757A JP2009525757A (ja) | 2009-07-16 |
| JP2009525757A5 true JP2009525757A5 (https=) | 2010-04-30 |
Family
ID=38459499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008554373A Pending JP2009525757A (ja) | 2006-02-10 | 2007-02-09 | 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１ |
| JP2012207821A Pending JP2013027398A (ja) | 2006-02-10 | 2012-09-21 | 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012207821A Pending JP2013027398A (ja) | 2006-02-10 | 2012-09-21 | 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7989606B2 (https=) |
| EP (2) | EP2441770A1 (https=) |
| JP (2) | JP2009525757A (https=) |
| CN (1) | CN101437833A (https=) |
| AU (1) | AU2007221470B2 (https=) |
| CA (1) | CA2638913A1 (https=) |
| WO (1) | WO2007100465A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101056539B (zh) | 2004-09-09 | 2012-12-12 | 综合医院公司 | 调节心脏细胞中的磷酸酶活性 |
| WO2009090049A1 (en) * | 2008-01-14 | 2009-07-23 | European Molecular Biology Laboratory | Peptides for the specific binding and regulation of protein targets |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| CN101942481B (zh) * | 2009-04-30 | 2012-07-25 | 中南大学 | 一种针对PKC γ基因RNA干扰的重组慢病毒载体的构建及其应用 |
| MX349622B (es) | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| WO2012109570A1 (en) | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| WO2014007584A1 (en) * | 2012-07-05 | 2014-01-09 | Gwangju Institute Of Science And Technology | Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban |
| ES2926774T3 (es) | 2013-03-15 | 2022-10-28 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores AAV de doble unión de glicano |
| US10907176B2 (en) | 2015-01-14 | 2021-02-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| HK1248554A1 (zh) | 2015-02-20 | 2018-10-19 | Board Of Regents, The University Of Texas System | 作为疫苗和载体的减毒衣原体的方法和组合物 |
| ES2865487T3 (es) | 2015-09-28 | 2021-10-15 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores virales que evaden los anticuerpos |
| NZ756587A (en) | 2017-03-15 | 2025-12-19 | Univ North Carolina Chapel Hill | Polyploid adeno-associated virus vectors and methods of making and using the same |
| EP3759218A4 (en) | 2018-02-28 | 2021-12-08 | The University of North Carolina at Chapel Hill | PROCEDURES AND COMPOSITIONS FOR ANTIBODY ELIMINATING VIRUS VECTORS |
| MX2020010465A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| EP3774852A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
| AU2019247748A1 (en) | 2018-04-03 | 2020-10-08 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| EP4169535A1 (en) | 2019-04-26 | 2023-04-26 | The University of North Carolina at Chapel Hill | Methods and compositions for dual glycan binding aav2.5 vector |
| JP2022551739A (ja) | 2019-10-17 | 2022-12-13 | ストライドバイオ，インコーポレイテッド | ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター |
| US12611436B2 (en) | 2019-10-17 | 2026-04-28 | Sarepta Therapeutics, Inc. | AAV transfer cassette |
| AU2021328475A1 (en) | 2020-08-19 | 2023-03-16 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of Rett syndrome |
| WO2022093769A1 (en) | 2020-10-28 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding aav2.5 vector |
| CN116490514A (zh) | 2020-10-28 | 2023-07-25 | 北卡罗来纳-查佩尔山大学 | 用于双重聚糖结合aav2.5载体的方法和组合物 |
| TW202242124A (zh) | 2021-01-14 | 2022-11-01 | 美商史崔德生物公司 | 靶向ｔ細胞之ａａｖ載體 |
| WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| TW202342759A (zh) | 2022-02-04 | 2023-11-01 | 美商史崔德生物公司 | 重組腺相關病毒載體及其使用方法 |
| WO2024124019A2 (en) | 2022-12-07 | 2024-06-13 | Ginkgo Bioworks, Inc. | Aav vectors targeting hematopoietic stem cells |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5252348A (en) | 1990-10-19 | 1993-10-12 | Univ. Of Florida Research Foundation, Inc. | Artificial viral envelopes |
| US5753258A (en) | 1990-10-19 | 1998-05-19 | University Of Florida | Artificial viral envelopes |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| DE69534166T2 (de) | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | Rekombinanter adenovirus und methoden zu dessen verwendung |
| JPH11514209A (ja) | 1995-04-20 | 1999-12-07 | カイロン コーポレイション | 組換えレトロウイルス調製物による造血幹細胞の高効率エクスビボ形質導入 |
| WO1997015679A1 (en) | 1995-10-27 | 1997-05-01 | The Trustees Of The University Of Pennsylvania | Recombinant viruses containing mobile genetic elements and methods of use in gene therapy |
| US6413544B1 (en) | 1996-08-19 | 2002-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| WO1998017683A2 (en) * | 1996-10-23 | 1998-04-30 | Duke University | Human phosphatase inhibitor-1 gene and methods of screening for non-insulin dependent diabetes mellitus |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| ATE318923T1 (de) | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
| US7201898B2 (en) | 2000-06-01 | 2007-04-10 | The University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
| ATE423574T1 (de) | 2000-09-11 | 2009-03-15 | Univ California | Dominant-negativer plb mutant zur behandlung der herzerkrankungen |
| US20040214760A1 (en) * | 2001-01-15 | 2004-10-28 | Ramesh Gupta | Inhibition pf protein-phosphatases for the treatment of heart failure |
| US20020159978A1 (en) * | 2001-02-06 | 2002-10-31 | James Allen | Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions |
| AU2003293124A1 (en) * | 2002-11-27 | 2004-06-23 | Artesian Therapeutics, Inc. | Heart failure gene determination and therapeutic screening |
| US20050066381A1 (en) | 2003-09-19 | 2005-03-24 | Children's Hospital Medical Center | Regulation of cardiac contractility and heart failure propensity |
| CN101056539B (zh) * | 2004-09-09 | 2012-12-12 | 综合医院公司 | 调节心脏细胞中的磷酸酶活性 |
-
2007
- 2007-02-09 CA CA002638913A patent/CA2638913A1/en not_active Abandoned
- 2007-02-09 EP EP11181884A patent/EP2441770A1/en not_active Withdrawn
- 2007-02-09 EP EP07750317A patent/EP1994043A4/en not_active Withdrawn
- 2007-02-09 US US12/162,499 patent/US7989606B2/en active Active
- 2007-02-09 AU AU2007221470A patent/AU2007221470B2/en not_active Ceased
- 2007-02-09 WO PCT/US2007/003470 patent/WO2007100465A2/en not_active Ceased
- 2007-02-09 JP JP2008554373A patent/JP2009525757A/ja active Pending
- 2007-02-09 CN CNA2007800120069A patent/CN101437833A/zh active Pending
-
2011
- 2011-08-02 US US13/196,450 patent/US8524683B2/en active Active
-
2012
- 2012-09-21 JP JP2012207821A patent/JP2013027398A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525757A5 (https=) | ||
| JP2018138049A5 (https=) | ||
| AU2007221470B2 (en) | Phosphatase inhibitor Protein-1 as a regulator of cardiac function | |
| JP2021521833A5 (https=) | ||
| JP2020531032A5 (https=) | ||
| JP2020518268A5 (https=) | ||
| JP2018171063A5 (https=) | ||
| US20120003201A1 (en) | Vault agents for chronic kidney disease | |
| JP2010516252A5 (https=) | ||
| JP2023518596A5 (https=) | ||
| JP2020517635A5 (https=) | ||
| JP2008536483A5 (https=) | ||
| JP2018538356A5 (https=) | ||
| BR112020004567A2 (pt) | polipeptídeos para o tratamento de doenças | |
| JP2008512484A5 (https=) | ||
| JP2018501791A5 (https=) | ||
| JP7604368B2 (ja) | ストレス症候群、免疫反応症候群及び卒中症候群の処置のためのポリペプチド | |
| JP2008506357A5 (https=) | ||
| JP2019524871A5 (https=) | ||
| JP2021521775A5 (https=) | ||
| JP2005519608A5 (https=) | ||
| JP2019521692A5 (https=) | ||
| JP2019512004A5 (https=) | ||
| JP2008521795A5 (https=) | ||
| EP2477646B1 (en) | Fusion proteins for use in the prevention or treatment of liver failure |